Document Detail

International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia.
MedLine Citation:
PMID:  14609804     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The authors compared the effects of the two most commonly used atypical antipsychotics, risperidone and olanzapine, in elderly patients with schizophrenia. METHODS: In an 8-week, international, double-blind study, patients (outpatients, hospital inpatients, and residents of nursing or boarding homes) were randomly assigned to receive risperidone (1 mg to 3 mg/day) or olanzapine (5 mg to 20 mg/day). The main outcome measures were changes in Positive and Negative Syndrome Scale (PANSS) total scores and rates of extrapyramidal symptoms (EPS). RESULTS: Subjects were 175 patients age 60 years or over with schizophrenia or schizoaffective disorder. The mean duration of illness was 36.5 years. Median doses were 2 mg/day of risperidone and 10 mg/day of olanzapine. PANSS total scores and four of the five PANSS factor scores (positive symptoms, negative symptoms, disorganized thoughts, and anxiety/depression) improved significantly at all time-points and at endpoint in both groups; between-treatment differences were not significant. EPS-related adverse events were reported by 9.2% of patients in the risperidone group and 15.9% in the olanzapine group; the between-treatment difference was not significant. Total scores on the Extrapyramidal Symptom Rating Scale were reduced in both groups at endpoint; between-treatment differences were not significant. Clinically relevant weight gain was seen in both groups, but was significantly less frequent in risperidone patients than in olanzapine patients. CONCLUSIONS: Stable elderly patients with chronic schizophrenia receiving appropriate doses of risperidone or olanzapine over an 8-week period experienced significant reductions in the severity of psychotic and extrapyramidal symptoms, with a relatively low risk of side effects.
Dilip V Jeste; Yoram Barak; Subramoniam Madhusoodanan; Fred Grossman; Georges Gharabawi
Related Documents :
16199834 - Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with...
24353414 - New developments in the management of copd: clinical utility of indacaterol 75 μg.
7504574 - Clinical review of risperidone.
8543544 - Risperidone as a treatment for tourette's syndrome.
25231564 - A minimum protocol for randomised homeopathic drug proving as basis for further research.
7970504 - Randomized trials of megestrol acetate for aids-associated anorexia and cachexia.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry     Volume:  11     ISSN:  1064-7481     ISO Abbreviation:  Am J Geriatr Psychiatry     Publication Date:    2003 Nov-Dec
Date Detail:
Created Date:  2003-11-11     Completed Date:  2004-03-12     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9309609     Medline TA:  Am J Geriatr Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  638-47     Citation Subset:  IM    
University of California, San Diego, CA 92161, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antipsychotic Agents / administration & dosage,  therapeutic use*
Benzodiazepines / therapeutic use*
Chronic Disease
Diagnostic and Statistical Manual of Mental Disorders
Double-Blind Method
Drug Administration Schedule
Risperidone / administration & dosage,  therapeutic use*
Schizophrenia / diagnosis,  drug therapy*
Severity of Illness Index
Reg. No./Substance:
0/Antipsychotic Agents; 106266-06-2/Risperidone; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine
Erratum In:
Am J Geriatr Psychiatry. 2004 Jan-Feb;12(1):49

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Functioning and well-being of middle-aged and older patients with schizophrenia: measurement with th...
Next Document:  Medicare and medicaid costs for schizophrenia patients by age cohort compared with costs for depress...